QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 8, 2009, 29(27):8669-8674; doi:10.1523/JNEUROSCI.1117-09.2009

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Yang, D. Articles by Kuan, C.-Y. PubMed PubMed Citation Articles by Yang, D. Articles by Kuan, C.-Y. Pubmed/NCBI databases Substance via MeSH

 Previous Article  |  Next Article 

Brief Communications
Therapeutic Administration of Plasminogen Activator Inhibitor-1 Prevents Hypoxic–Ischemic Brain Injury in Newborns

Dianer Yang,¹ Niza Nemkul,¹ Ahmed Shereen,² Alice Jone,¹ R. Scott Dunn,² Daniel A. Lawrence,³ Diana Lindquist,² and Chia-Yi Kuan¹

¹Division of Developmental Biology and Division of Neurology, ²Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, and ³Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109

Correspondence should be addressed to Dr. Chia-Yi Kuan, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229. Email: alex.kuan{at}cchmc.org

Disruption of the integrity of the blood–brain barrier (BBB) is an important mechanism of cerebrovascular diseases, including neonatal cerebral hypoxia–ischemia (HI). Although both tissue-type plasminogen activator (tPA) and matrix metalloproteinase-9 (MMP-9) can produce BBB damage, their relationship in neonatal cerebral HI is unclear. Here we use a rodent model to test whether the plasminogen activator (PA) system is critical for MMP-9 activation and HI-induced brain injury in newborns. To test this hypothesis, we examined the therapeutic effect of intracerebroventricular injection of plasminogen activator inhibitor-1 (PAI-1) in rat pups subjected to unilateral carotid artery occlusion and systemic hypoxia. We found that the injection of PAI-1 greatly reduced the activity of both tPA and urokinase-type plasminogen activator after HI. It also blocked HI-induced MMP-9 activation and BBB permeability at 24 h of recovery. Furthermore, magnetic resonance imaging and histological analysis showed the PAI-1 treatment reduced brain edema, axonal degeneration, and cortical cell death at 24–48 h of recovery. Finally, the PAI-1 therapy provided a dose-dependent decrease of brain tissue loss at 7 d of recovery, with the therapeutic window at 4 h after the HI insult. Together, these results suggest that the brain PA system plays a pivotal role in neonatal cerebral HI and may be a promising therapeutic target in infants suffering hypoxic–ischemic encephalopathy.

---

Received March 7, 2009; revised May 8, 2009; accepted June 1, 2009.

Correspondence should be addressed to Dr. Chia-Yi Kuan, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229. Email: alex.kuan{at}cchmc.org

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help